The high efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis
(MS) is without controversy. Indeed, effective disease control was not only demonstrated in …

Background and Objectives Some patients with multiple sclerosis (MS) receiving
ocrelizumab (OCR) report worsening symptoms toward the end of the 6-month infusion cycle …

Abstract Motor fatigue in Multiple Sclerosis (MS) is due to reduced motor cortex (M1) output
and altered sensorimotor network (SMN) modulation. Natalizumab, a disease-modifying …

Background Patients with multiple sclerosis (MS) who are treated with monoclonal
antibodies frequently report an increase of MS-related symptoms prior to the next dose …

Despite its widespread use in clinical practice, the effectiveness of natalizumab extended
interval dosing (EID) adopted from treatment start across different treatment intervals and …

Background: Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL)
and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of …

Background Many patients treated with Natalizumab experience wearing-off symptoms
(WoS) towards the end of the administration cycle. During the pandemic we advised and …

Aim: Patients with relapsing–remitting multiple sclerosis (RRMS) treated with natalizumab
have anecdotally reported a 'feel-good experience'(FGE). The authors characterized the …

Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis, but
many treated patients report subjective wearing-off symptoms at the end of the 4-week …

Objective The wearing-off phenomenon is common in people with multiple sclerosis (MS)
treated with ocrelizumab. We aim to evaluate the presence and severity of wearing-off to …